Search research articles
Contact Us
Filters
Showing results (301-310 of 326) with videos related to
Page
of 33
Sort By:
JHEP Reports : Innovation in Hepatology
|
September 29, 2023
Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
Young-Suk Lim, Henry L Y Chan, Sang Hoon Ahn, et al.
The Lancet. Gastroenterology & Hepatology
|
April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Henry L Y Chan, Scott Fung, Wai Kay Seto, et al.
Alimentary Pharmacology & Therapeutics
|
September 27, 2024
Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
Maria Buti, Young-Suk Lim, Henry Lik Yuen Chan, et al.
Journal of Hepatology
|
January 29, 2022
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels
Milan J Sonneveld, Shao-Ming Chiu, Jun Yong Park, et al.
JHEP Reports : Innovation in Hepatology
|
July 24, 2023
Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort study
Milan J Sonneveld, Shao-Ming Chiu, Jun Yong Park, et al.
Gastroenterology
|
November 11, 2021
Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study)
Grishma Hirode, Hannah S J Choi, Chien-Hung Chen, et al.
The American Journal of Gastroenterology
|
January 31, 2023
Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal: Results From a Large, International, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study)
Grishma Hirode, Bettina E Hansen, Chien-Hung Chen, et al.
The American Journal of Gastroenterology
|
March 8, 2024
Correction to: Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal: Results From a Large, International, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study)
Grishma Hirode, Bettina E Hansen, Chien-Hung Chen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 21, 2022
Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B
Hannah S J Choi, Grishma Hirode, Chien-Hung Chen, et al.
The American Journal of Gastroenterology
|
March 14, 2024
Limited Sustained Remission After Nucleos(t)ide Analog Withdrawal: Results From a Large, Global, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study)
Grishma Hirode, Bettina E Hansen, Chien-Hung Chen, et al.
Page
of 33
Search research articles
Search
Showing results (301-310 of 326) with videos related to
Sort By:
Page
of 33
JHEP Reports : Innovation in Hepatology
|
September 29, 2023
Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
Young-Suk Lim, Henry L Y Chan, Sang Hoon Ahn, et al.
The Lancet. Gastroenterology & Hepatology
|
April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Henry L Y Chan, Scott Fung, Wai Kay Seto, et al.
Alimentary Pharmacology & Therapeutics
|
September 27, 2024
Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
Maria Buti, Young-Suk Lim, Henry Lik Yuen Chan, et al.
Journal of Hepatology
|
January 29, 2022
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels
Milan J Sonneveld, Shao-Ming Chiu, Jun Yong Park, et al.
JHEP Reports : Innovation in Hepatology
|
July 24, 2023
Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort study
Milan J Sonneveld, Shao-Ming Chiu, Jun Yong Park, et al.
Gastroenterology
|
November 11, 2021
Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study)
Grishma Hirode, Hannah S J Choi, Chien-Hung Chen, et al.
The American Journal of Gastroenterology
|
January 31, 2023
Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal: Results From a Large, International, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study)
Grishma Hirode, Bettina E Hansen, Chien-Hung Chen, et al.
The American Journal of Gastroenterology
|
March 8, 2024
Correction to: Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal: Results From a Large, International, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study)
Grishma Hirode, Bettina E Hansen, Chien-Hung Chen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 21, 2022
Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B
Hannah S J Choi, Grishma Hirode, Chien-Hung Chen, et al.
The American Journal of Gastroenterology
|
March 14, 2024
Limited Sustained Remission After Nucleos(t)ide Analog Withdrawal: Results From a Large, Global, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study)
Grishma Hirode, Bettina E Hansen, Chien-Hung Chen, et al.
Page
of 33